BR112022001184A2 - Composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1 - Google Patents

Composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1

Info

Publication number
BR112022001184A2
BR112022001184A2 BR112022001184A BR112022001184A BR112022001184A2 BR 112022001184 A2 BR112022001184 A2 BR 112022001184A2 BR 112022001184 A BR112022001184 A BR 112022001184A BR 112022001184 A BR112022001184 A BR 112022001184A BR 112022001184 A2 BR112022001184 A2 BR 112022001184A2
Authority
BR
Brazil
Prior art keywords
cx3cr1
modulating
treating
compound
formula
Prior art date
Application number
BR112022001184A
Other languages
English (en)
Inventor
Ali Yousif
Chiara Liberati
Domenica Torino
Francesco Piscitelli
Mary Hamby
Paolo Pevarello
Philip Jones
Russell Thomas
Silvia Bovolenta
Valentina Cusano
William Ray
Luzardo Lightfoot Yaima
Original Assignee
Axxam Spa
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axxam Spa, Univ Texas filed Critical Axxam Spa
Publication of BR112022001184A2 publication Critical patent/BR112022001184A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • C07D333/80—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1. são divulgados no presente documento novos compostos de cicloalca[b]heteroarila com propriedades agonistas do receptor cx3cr1/de fractalcina (cx3cr1), composições farmacêuticas compreendendo esses compostos, processos químicos para a preparação desses compostos e seu uso no tratamento ou profilaxia de doenças associadas à atividade do receptor cx3cr1 em animais, particularmente seres humanos.
BR112022001184A 2019-07-23 2020-07-23 Composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1 BR112022001184A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962877660P 2019-07-23 2019-07-23
PCT/US2020/043258 WO2021016449A1 (en) 2019-07-23 2020-07-23 Bicyclic cx3cr1 receptor agonists

Publications (1)

Publication Number Publication Date
BR112022001184A2 true BR112022001184A2 (pt) 2022-03-15

Family

ID=74189124

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001184A BR112022001184A2 (pt) 2019-07-23 2020-07-23 Composto da fórmula (i), composição farmacêutica, método de tratamento de uma doença mediada por cx3cr1 e método de modulação de cx3cr1

Country Status (11)

Country Link
US (3) US11155538B2 (pt)
EP (1) EP4003972A4 (pt)
JP (1) JP2022541627A (pt)
KR (1) KR20220090492A (pt)
CN (1) CN114929681B (pt)
AU (1) AU2020316080A1 (pt)
BR (1) BR112022001184A2 (pt)
CA (1) CA3148454A1 (pt)
IL (1) IL290024A (pt)
MX (1) MX2022000917A (pt)
WO (1) WO2021016449A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220090492A (ko) 2019-07-23 2022-06-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 바이시클릭 cx3cr1 수용체 작용제

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401969D0 (sv) * 2004-08-02 2004-08-02 Astrazeneca Ab Piperidine derivatives
WO2009086303A2 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
UY32443A (es) * 2009-02-13 2010-09-30 Sanofi Aventis Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento.
WO2012012322A1 (en) 2010-07-19 2012-01-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2012078633A2 (en) * 2010-12-07 2012-06-14 Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene Methods of inhibiting metastasis from cancer
CN104744451A (zh) * 2013-12-30 2015-07-01 中国科学院上海药物研究所 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途
CA2946062C (en) * 2014-04-17 2023-02-28 Institut Pasteur Korea Compounds for treating viral infections
WO2018204370A1 (en) * 2017-05-02 2018-11-08 Drexel University Cx3cr1 small molecule antagonists, and methods using same
KR20220090492A (ko) 2019-07-23 2022-06-29 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 바이시클릭 cx3cr1 수용체 작용제

Also Published As

Publication number Publication date
CN114929681B (zh) 2024-05-14
CA3148454A1 (en) 2021-01-28
JP2022541627A (ja) 2022-09-26
IL290024A (en) 2022-03-01
EP4003972A4 (en) 2023-07-12
US20220259191A1 (en) 2022-08-18
WO2021016449A1 (en) 2021-01-28
US11155538B2 (en) 2021-10-26
AU2020316080A1 (en) 2022-03-03
MX2022000917A (es) 2022-04-07
US11958839B2 (en) 2024-04-16
US20210024510A1 (en) 2021-01-28
EP4003972A1 (en) 2022-06-01
CN114929681A (zh) 2022-08-19
US20240150332A1 (en) 2024-05-09
KR20220090492A (ko) 2022-06-29

Similar Documents

Publication Publication Date Title
ECSP20069418A (es) Compuestos heterocíclicos como inmunomoduladores
BR112021022624A2 (pt) Compostos para o tratamento da doença de huntington
ECSP19030002A (es) 1,2,4-triazolonas 2,4,5-trisustituidas
BR112018070602A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio
BR112019012217A2 (pt) compostos de amino-triazolopiridina e seu uso no tratamento de câncer
BR112019016497A2 (pt) 2-heteroaril-3-oxo-2,3-di-hidropiridazina-4-carboxamidas para o tratamento de câncer.
BRPI0912475B8 (pt) compostos como inibidores de quinase, método para produção dos ditos compostos e composição farmacêutica
BRPI0507801A (pt) compostos de azetidina substituìda, processo para a preparação de compostos de azetidina substituìda, medicamento e uso de pelo menos um composto de azetidina substituìda
BR112016030730A8 (pt) composto
BR112017004173A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou condição patológica.
CL2022000998A1 (es) Inhibidores de las cinasas raf
BR112021025964A2 (pt) Formas de sal de ácido bempedoico e métodos para uso das mesmas
BRPI0519135A2 (pt) macrolÍdeos
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
BR112013006030A2 (pt) composto e sais, solvatos, n-óxidos ou prodrogas farmaceuticamente aceitáveis, composição farmacêutica, uso do composto, kit, método de tratamento de uma doença, e, composição anti-helmíntica
MX2022007455A (es) Derivados de isoxazolina como plaguicidas.
BR112022010082A2 (pt) Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica
DOP2021000198A (es) Compuestos y su uso en el tratamiento del cáncer
BR112021021477A2 (pt) Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo
BR112021018631A2 (pt) Compostos anti-helmínticos de aza-benzotiofeno e aza-benzofurano
BR112021021649A2 (pt) Composições farmacêuticas injetáveis e usos das mesmas
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
BR112022020147A2 (pt) Compostos para tratar a doença de huntington

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]